What is Fumagillin, and what are its primary uses?

Fumagillin is a natural antibiotic that inhibits angiogenesis by targeting methionine aminopeptidase 2 (MetAP-2). It is used in cancer research to prevent tumor growth by blocking blood vessel formation.

Which cancer types are typically targeted using Fumagillin-based therapies?

Fumagillin has shown promise in treating solid tumors like lung, breast, and colon cancer, where angiogenesis is a critical factor for tumor growth and metastasis.

What are the potential side effects of using Fumagillin in cancer research?

Fumagillin may cause side effects such as weight loss, neurotoxicity, and gastrointestinal issues, though targeted delivery via ADCs can help minimize these risks.

What challenges are associated with using Fumagillin in therapeutic applications?

Fumagillin has known toxicities, particularly at higher doses. ADCs help mitigate these by providing targeted delivery, but dose optimization remains a key challenge in its therapeutic use.

Does Creative Biolabs offer custom Fumagillin ADC development?

Yes, Creative Biolabs provides custom Fumagillin-based ADC development services, enabling researchers to create targeted anti-angiogenic therapies for specific cancer types.

Fumagillin (CAT#: ADC-P-091)

ADCs Toxins, Fumagillin is a methionine aminopeptidase-2 (MetAP-2) inhibitor; Fumagillin inhibits endothelial cell proliferation and angiogenesis. Fumagillin belongs to the group of mycotoxins. Origin: Aspergillus fumigatus

Product Information

CAS NO
23110-15-8

Description
ADCs Toxins, Fumagillin is a methionine aminopeptidase-2 (MetAP-2) inhibitor; Fumagillin inhibits endothelial cell proliferation and angiogenesis. Fumagillin belongs to the group of mycotoxins. Origin: Aspergillus fumigatus

Classification
Others

Molecular Weight
458.6

Purity
95%

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-P-091. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

We utilized Fumagillin in our ADC development, where its MetAP-2 inhibition enhanced the anti-proliferative effects of our conjugates on endothelial cells, contributing to better targeted drug efficacy.

Excellent

Fumagillin demonstrated impressive activity in our angiogenesis assays, significantly reducing endothelial cell growth. This compound has been instrumental in our studies focusing on blood vessel formation inhibition.

Excellent

In our ADC research, Fumagillin was a potent toxin. Its ability to inhibit MetAP-2 provided a synergistic effect with our drug conjugates, leading to improved therapeutic outcomes in cancer models.

Excellent

We employed Fumagillin in our ADC experiments and saw a remarkable reduction in angiogenesis. Its ability to inhibit endothelial cell proliferation was particularly beneficial in enhancing the potency of our conjugates.

Excellent

Fumagillin served as a critical tool in our research on mycotoxins and their effects on cell proliferation. Its inhibition of MetAP-2 allowed us to study cell cycle regulation more thoroughly.

Q: 1: What is Fumagillin, and what are its primary uses?
A: Fumagillin is a natural antibiotic that inhibits angiogenesis by targeting methionine aminopeptidase 2 (MetAP-2). It is used in cancer research to prevent tumor growth by blocking blood vessel formation.
Q: 2: Which cancer types are typically targeted using Fumagillin-based therapies?
A: Fumagillin has shown promise in treating solid tumors like lung, breast, and colon cancer, where angiogenesis is a critical factor for tumor growth and metastasis.
Q: 3: What are the potential side effects of using Fumagillin in cancer research?
A: Fumagillin may cause side effects such as weight loss, neurotoxicity, and gastrointestinal issues, though targeted delivery via ADCs can help minimize these risks.
Q: 4: What challenges are associated with using Fumagillin in therapeutic applications?
A: Fumagillin has known toxicities, particularly at higher doses. ADCs help mitigate these by providing targeted delivery, but dose optimization remains a key challenge in its therapeutic use.
Q: 5: Does Creative Biolabs offer custom Fumagillin ADC development?
A: Yes, Creative Biolabs provides custom Fumagillin-based ADC development services, enabling researchers to create targeted anti-angiogenic therapies for specific cancer types.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

For Research Use Only. NOT FOR CLINICAL USE.

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Creative Biolabs quality assurance certification